COVID-19 disease has dramatically demonstrated the fundamental role of angiotensin-converting enzyme 2 and its active product angiotensin 1-7 (Ang 1-7) in the inhibitory control of cytokine-induced inflammatory response, whose importance was not taken into consideration in the clinical practices. On the contrary, several experimental and clinical studies have shown that Ang 1-7 in addition to its hypotensive and cardioprotective actions may also play anti-inflammatory, antitumor, antithrombotic, and antifibrotic effects, then a potential regenerative activity. Most systemic human diseases, including advanced cancer, autoimmunity, cardiovascular disease, neurodegenerative pathologies, metabolic syndrome, and aging itself would be characterized by a reduced Ang 1-7 production and activity. Unfortunately, despite its potential universal therapeutic properties and its lack of toxicity, at present, few clinical studies have been performed to evaluate the therapeutic efficacy of Ang 1-7 in the different human pathologies in an attempt to prolong the duration of life.